Abstract
We firstly verified the specific killing effect of CAR-NK92 cells. Through modeling we rejected the plan to express diverse CARs on a single NK92 cell, which led us to express a CAR library on a group of NK92 cells to make up a CAR-NK92 library. We then verified the feasibility of the kill switch circuit and the growth dynamics of logic-gated NK-92 cells according to antigens. Together with statistics we gathered from modeling, we can preliminarily demonstrate that our project is feasible and promising in tumor therapy, especially in addressing tumor heterogeneity.
Our modeling work is detailed in MODELS.
Experiments
1.verification of the specific killing effect of CAR-NK92 cells
Material:
①Engineered cell: NK-92-CTX and NK-92-TTZ
②Target cell: MCF-7 cells (EGFR-HER2-), MCF-7 EGFR+ cells and MCF-7 HER2+ cells
Method:
fluorescent target array killing assays
Result:
NK-92 cells with no CAR performed no killing effect and NK-92-CTX or NK-92-TTZ had specific killing effect only when they encountered corresponding antigens, which verified the specific killing effect of CAR-NK92 cells.
2.verification of the feasibility of the kill switch circuit
Material:
①Engineered cell: NK-92-CTX and NK-92-TTZ, engineered with kill switch circuit
②Target cell: MCF-7 cells (EGFR-HER2-), MCF-7 EGFR+ cells and MCF-7 HER2+ cells
Method:
co-culture experiment
Result:
Our data showed that AP1903 had no effect on the viability of NK-92 cells but caused apoptosis/necrosis of the engineered NK92 cells with no stimulatory cells. However, after 24h of stimulation with specific antigens, the engineered NK92 cells were notably affected by the reduced pro-apoptotic effect of AP1903, and both the EGFR-specific and HER2-specific CAR-NK92 cells were resistant to AP1903 after antigen stimulation for 72h.
3.verification of the growth dynamics of logic-gated NK-92 cells according to antigens
While AP1093 extensively induces apoptosis, we want to ensure that CAR-NK92 cells that recognize the corresponding antigen, could continue to proliferate and enrich without interference. To achieve this goal, we introduced the suicide repressor section.
Material:
①Engineered cell: a group of NK-92 cells engineered with 10 different kinds of CARs and the kill switch circuit, making up a 10-CAR-NK92 library.
The origin of 10 CARs: cetuximab, trastuzumab, CH65, 9.8B, 2F5, 7D11, 8D6, omalizumab, TE33, and R10
②Target cell: MCF-7 cells (EGFR-HER2-), MCF-7 EGFR+ cells and MCF-7 HER2+ cells
Method:
co-culture experiment
Result:
Repeat stimulations with MCF-7 EGFR cells or MCF-7 HER2 cells resulted in no significant change in the CAR composition of the library co-cultured with either MCF-7 cells or antigen-positive MCF-7 derivatives without AP1903 treatment, while enrichment of NK-92 CTX and NK-92 TTZ cells was observed after AP1903 treatment in the presence of specific MCF-7 derivatives. These data suggest that the gene circuit was effective in the cell-based CAR screening method and adding AP1903 was essential for the enrichment of CAR NK-92 cells.